Orelabrutinib Cuts Progression Risk 68% in Frontline CLL/SLL

Orelabrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, significantly outperformed standard chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to results from a randomized, open-label phase 3 trial (NCT04578613).¹ The risk of disease progression or death dropped by 68% compared with chemotherapy of chlorambucil plus rituximab, meeting the trial’s primary end point of progression-free survival (PFS) and crossing the prespecified efficacy boundary at interim analysis.

The findings, published in Signal Transduction and Targeted Therapy, reflect the first head-to-head phase 3 comparison of orelabrutinib against chemoimmunotherapy in the frontline CLL/SLL setting, the authors highlighted.

What Do These Trial Data Demonstrate?

A total of 358 patients were screened for study inclusion before being randomly assigned to continuous treatment with orelabrutinib (n = 91) or up to 6 cycles of chlorambucil plus rituximab (n = 101). Overall, 100% of the orelabrutinib group received its assigned treatment, and 97% of the control group received its assigned treatment.

The data cutoff for interim analysis was May 17, 2024. At this deadline, the median follow-up was 13.7% longer (2.7 months) for the patients who received orelabrutinib compared with the combination: 22.4 months (range, 1.9-40.3) vs 19.7 months (range, 0.03-38.7), respectively. Twenty-two patients (24.2%) who received orelabrutinib discontinued treatment.

At a median overall follow-up of 21.4 months (range, 0.03–40.3), median PFS was not reached in the orelabrutinib arm vs 19.4 months with chemoimmunotherapy, for a 68% reduced risk of disease progression or death (HR, 0.32; 95% CI, 0.18-0.58; P < .0001). Overall response rate favored orelabrutinib as well (90.1% [95% CI, 82.1%-95.4%] vs 79.2% [95% CI, 70.0%-86.6%]; P = .041). Duration of response was not reached in either study arm, but was superior among those who received orelabrutinib (HR, 0.30; 95% CI, 0.15-0.60; P = .0003) at 12 and 24 months:

• 12 months: 90.3% (95% CI, 80.7%-95.3%) vs 71.2% (95% CI, 58.7%-80.6%)
• 24 months: 84.3% (95% CI, 72.4%-91.4%) vs 51.7% (95% CI, 36.9%-64.7%)

The PFS benefit held across prespecified subgroups, including patients with high-risk features such as unmutated IGHV status, del(11q), and complex karyotype—populations that have historically fared worse on chemoimmunotherapy. There were 5 patient deaths in the orelabrutinib cohort and 11 in the chlorambucil–rituximab cohort.

Despite an approximate quadruple of the treatment duration, orelabrutinib was associated with a comparable overall rate of treatment-related adverse events (90.1% vs 90.8%) but notably fewer grade 3 or higher events (35.2% vs 60.2%) than chlorambucil-rituximab. Grade 3 or higher hematologic toxicity by International Workshop on Chronic Lymphocytic Leukemia criteria was less frequent with orelabrutinib (14.3% vs 33.7%), and no treatment-related atrial fibrillation, major bleeding, or second primary malignancies were reported with the BTK inhibitor as of the data cutoff. Median treatment durations were 4.7 months for rituximab, 5.2 months for chlorambucil, and 19.3 months for orelabrutinib.

Earlier-generation BTK inhibitors have been associated with off-target cardiovascular effects such as atrial fibrillation and hypertension,² so the absence of these events is notable, although investigators cautioned that the relatively short follow-up warrants caution in drawing firm conclusions about long-term cardiac risk.

The Importance of BTK Selectivity

Orelabrutinib was designed for high BTK selectivity and sustained target occupancy, which the investigators say may explain its more favorable off-target safety profile relative to first-generation agents like ibrutinib, historically linked to cardiac events, hypertension, and bleeding.

Patient-reported quality-of-life measures also favored orelabrutinib over later treatment cycles, with greater improvement observed from cycle 16 onward. Using score changes on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Global Health Status/Quality of Life subscale, the investigators saw a 10.2-point improvement for the patients who received orelabrutinib vs a 5.2-point decline for those who received chlorambucil-rituximab. Similarly, via the EuroQol 5-Dimension 3-Level Visual Analogue Scale, the least squares mean change from baseline to cycle 37 was 11.3, favoring orelabrutinib.

For payers and health systems, the data reinforce a broader trend toward continuous oral targeted therapy as a frontline standard in CLL/SLL. The authors note that optimal first-line therapy should be individualized through shared decision-making between patients and their care team, weighing treatment goals, risks, benefits, cost, and access alongside newer fixed-duration regimens now entering the same treatment space.

“The clinically meaningful benefit, along with favorable safety and maintained QOL indicate a favorable benefit-risk profile of orelabrutinib,” the authors concluded, “establishing it as an effective and safe option for this population.”

Still, they cautioned against generalizing their findings because of several prominent limitations. This study used an open-label design; there was no standard-of-care comparator; the study population was exclusively Chinese; and patients with del(17p)/TP53-mutated disease were excluded. Also, the follow-up was short, and overall survival data remain immature.

References

1. Lei F, Zhou K, Xu W, et al. Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial. Signal Transduct Target Ther. 2026;11(1):261. doi:10.1038/s41392-026-02818-x
2. McNulty R. Applications, future directions of BTK Inhibitors in blood cancers and autoimmune disorders. AJMC^®. October 14, 2022. Accessed August 8, 2026. https://www.ajmc.com/view/applications-future-directions-of-btk-inhibitors-in-blood-cancers-and-autoimmune-disorders